Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gut microbiome has an important role to play in ICI response7,8, as we also confirmed here”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Although we confirmed that the microbiome holds the potential to support the clinical practice for the treatment of patients with melanoma, as shown via fecal microbiota transplantation pilots7,8”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Furthermore, two clinical trials unexpectedly found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients in 2021 [14, 15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“The results showed that three of the ten patients showed tumor volume decline, including two partial responses (PR) and one complete response (CR) [15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Conservation evaluation and phylogenetic diversity
Faith, D. P. (1992) · Biological Conservation · doi:10.1016/0006-3207(92)91201-3 · Cited by 5,693
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Self-citation
Cited by
Items 501–600 of 1,002
Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response
Chai, Y., Huang, Z., Shen, X., Lin, T., Zhang, Y., Xu, F., Mao, Q., & Liang, Y. (2023) · Microorganisms · doi:10.3390/microorganisms11051240 · Cited by 29
Gastric microbiota: an emerging player in gastric cancer
Zhou, S., Li, C., Liu, L., Yuan, Q., Miao, J., Wang, H., Ding, C., & Guan, W. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1130001 · Cited by 35
Duttagupta, S., Hakozaki, T., Routy, B., & Messaoudene, M. (2023) · Current Oncology · doi:10.3390/curroncol30110681 · Cited by 31
Tini, S., Baima, J., Pigni, S., Antoniotti, V., Caputo, M., Palma, E. D., Cerbone, L., Grosso, F., Vecchia, M. L., Bona, E., et al. (2025) · Nutrients · doi:10.3390/nu17172898 · Cited by 30
Influence of the microbiome on solid organ transplant survival
Pirozzolo, I., Li, Z., Sepulveda, M., & Alegre, M. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.004 · Cited by 27
The Role of Gut Microbiota in Modulating Tumor Growth and Anticancer Agent Efficacy
Kim, J.-H., & Lee, H. K. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0032 · Cited by 29
Cancer and immunotherapy: a role for microbiota composition
Pham, F., Moinard‐Butot, F., Coutzac, C., & Chaput, N. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.051 · Cited by 29
Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy
Bae, J., Park, K., & Kim, Y. (2022) · Immune Network · doi:10.4110/in.2022.22.e3 · Cited by 32
The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection
Oster, P., Vaillant, L., McMillan, B., & Velin, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.899161 · Cited by 32
Selected commensals educate the intestinal vascular and immune system for immunocompetence
Romero, R., Zarzycka, A., Preußner, M., Fischer, F., Hain, T., Herrmann, J.-P., Roth, K. S., Keber, C. U., Suryamohan, K., Raifer, H., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01353-5 · Cited by 30
Holmstroem, R. B., Dahl, E. K., Helms, M., Nielsen, H. V., Andersen, J. B., Bjerrum, J. T., Svane, I. M., Ellebæk, E., & Seidelin, J. B. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2022-000989 · Cited by 30
Borgers, J. S. W., Burgers, F. H., Terveer, E. M., van Leerdam, M. E., Korse, C. M., Kessels, R., Flohil, C. C., Blank, C. U., Schumacher, T. N., van Dijk, M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10457-y · Cited by 33
Knisely, A. T., Seo, Y. D., Wargo, J. A., & Chelvanambi, M. (2023) · Cancers · doi:10.3390/cancers15030777 · Cited by 32
Self-citationRomán, M. S., Torres-Jiménez, J., Pozas, J., Esteban-Villarrubia, J., Albarrán, V., Ballesteros, P. Á., Chamorro-Pérez, J., Rodriguez, D. I. R., Orejana, I., Martínez-Delfrade, Í., et al. (2023) · Cancers · doi:10.3390/cancers15030863 · Cited by 30
Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma
Witt, R. G., Cass, S. H., Tran, T., Damania, A. V., Nelson, E. E., Sirmans, E., Burton, E. M., Chelvanambi, M., Johnson, S. B., Tawbi, H. A., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.2955 · Cited by 28
Self-citationThe Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives
Uher, O., Vanova, K. H., Taïeb, D., Calsina, B., Robledo, M., Clifton-Bligh, R. J., & Pacák, K. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae005 · Cited by 31
Paternostro, R., Sieghart, W., Trauner, M., & Pinter, M. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100185 · Cited by 31
Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy
Zhou, Y., Liu, Z., & Chen, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847350 · Cited by 32
Yang, S., Zhao, S., Ye, Y., Jia, L., & Lou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952546 · Cited by 32
Pallozzi, M., Tommaso, N. D., Maccauro, V., Santopaolo, F., Gasbarrini, A., Ponziani, F. R., & Pompili, M. (2022) · Cancers · doi:10.3390/cancers14194631 · Cited by 28
Perry, L. M., Cruz, S. M., Kleber, K. T., Judge, S. J., Darrow, M. A., Jones, L. B., Basmaci, U. N., Joshi, N., Settles, M. L., Durbin-Johnson, B. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004285 · Cited by 30
Microbial metabolites and immunotherapy: Basic rationale and clinical indications
Kovtonyuk, L. V., & McCoy, K. D. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101755 · Cited by 27
A narrative review from gut to lungs: non-small cell lung cancer and the gastrointestinal microbiome
Shah, H., & Ng, T. L. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-595 · Cited by 27
Precision Probiotic Medicine to Improve ICB Immunotherapy
Luccia, B. D., & Colonna, M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0221 · Cited by 24
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Messaoudene, M., Ferreira, S., Saint-Lu, N., Ponce, M., Truntzer, C., Boidot, R., Le Bescop, C., Loppinet, T., Corbel, T., Féger, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52373-8 · Cited by 24
Gut microbiota and immune alteration in cancer development: implication for immunotherapy
Lau, H. C.-H., Zhang, X., & Yu, J. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100007 · Cited by 25
PD ‐1: A critical player and target for immune normalization
Liu, X., Zhao, A., Xiao, S., Li, H., Li, M., Guo, W., & Han, Q. (2024) · Immunology · doi:10.1111/imm.13755 · Cited by 29
Metabolic immunoengineering approaches to enhance CD8+ T cell-based cancer immunotherapy
Feng, B., Li, R., Li, W., & Tang, L. (2024) · Cell Systems · doi:10.1016/j.cels.2024.11.010 · Cited by 29
Dong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101215 · Cited by 29
The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma
Yao, J., Ning, B., & Ding, J. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2473504 · Cited by 28
Systems Human Immunology and AI: Immune Setpoint and Immune Health
Lei, Y., & Tsang, J. S. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090122-042631 · Cited by 31
Wang, L., Jiang, W., Yang, M., Danzeng, Q., Liu, S., & Cui, M. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02275-z · Cited by 29
Microbiome Modulation for the Treatment of Solid Neoplasms
Barragán-Carrillo, R., Zengin, Z. B., & Pal, S. K. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00374 · Cited by 33
The microbiome, gastrointestinal cancer, and immunotherapy
Newsome, R. C., Yang, Y., & Jobin, C. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15742 · Cited by 28
Poizeau, F., Kerbrat, S., Balusson, F., Tattevin, P., Revest, M., Cattoir, V., Paz, D. L., Lesimple, T., Pracht, M., Dinulescu, M., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac019 · Cited by 28
Evaluating live microbiota biobanking using an ex vivo microbiome assay and metaproteomics
Zhang, X., Walker, K., Mayne, J., Li, L., Ning, Z., Stintzi, A., & Figeys, D. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2035658 · Cited by 28
Lefler, D. S., Snook, A. E., & Bashir, B. (2022) · Immunotherapy · doi:10.2217/imt-2022-0012 · Cited by 25
Higbie, V. S., Rogers, J. E., Hwang, H., Qiao, W., Xiao, L., Dasari, A. N., Mola-Rudd, K., Morris, V. K., Wolff, R. A., Raghav, K. P. S., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac162 · Cited by 23
Creskey, M., Li, L., Ning, Z., Fekete, E. E. F., Mayne, J., Walker, K., Ampaw, A. A., Ben, R. N., Zhang, X., & Figeys, D. (2022) · PROTEOMICS · doi:10.1002/pmic.202200116 · Cited by 24
How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?
Mendes, I., & Vale, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411855 · Cited by 24
Park, J. S., Gazzaniga, F. S., Kasper, D. L., & Sharpe, A. H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01075-0 · Cited by 25
Impact of the ONCOBIOME network in cancer microbiome research
Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03608-8 · Cited by 23
Chang, J. W., Hsieh, J., Tsai, C.-Y., Chiu, H.-Y., Lin, Y.-F., Wu, C., Shen, Y., Hou, M., Chang, C.-Y., Chen, J.-A., et al. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100698 · Cited by 27
Hu, N., Li, H., Tao, C., Xiao, T., & Rong, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115584 · Cited by 34
Lim, M. Y., Hong, S., & Nam, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512683 · Cited by 27
Acquired resistance to immunotherapy in solid tumors
Verdys, P., Johansen, A. Z., Gupta, A. K., Presti, M., Dionisio, E., Madsen, D. H., Fontecedro, A. C., & Donia, M. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.03.010 · Cited by 32
New insights into gut microbiota–prostate cancer crosstalk
Laaraj, J., Lachance, G., Bergeron, A., Fradet, Y., Robitaille, K., & Fradet, V. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.03.015 · Cited by 27
Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
Eiman, L., Moazzam, K., Anjum, S., Kausar, H., Sharif, E. A. M., & Ibrahim, W. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1575452 · Cited by 32
Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review
Petrelli, F., Ghidini, A., Dottorini, L., Ghidini, M., Zaniboni, A., & Tomasello, G. (2025) · Medicina · doi:10.3390/medicina61091595 · Cited by 33
First clinical proof-of-concept that FMT can overcome resistance to ICIs
Elkrief, A., & Routy, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00502-3 · Cited by 23
“Baruch et al.(9) 10 patients with ICIrefractory metastatic melanoma 2 donors with melanoma and a CR to ICIs lasting >1 year; colonoscopy (1 ×), followed by oral capsules for 6 cycles 1 CR and 2 PRs (all among 5 patients with FMT from donor 1); no grade ≥2 irAEs Stronger clustering of postFMT microbiome with donor 1 vs…”
BackgroundDirecting T-Cell Immune Responses for Cancer Vaccination and Immunotherapy
Smith, P. L., Piadel, K., & Dalgleish, A. G. (2021) · Vaccines · doi:10.3390/vaccines9121392 · Cited by 24
Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons
Luo, Y., Teng, F., Fu, H. Y., & Ding, G. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i1.163 · Cited by 25
von Itzstein, M. S., Gonugunta, A. S., Sheffield, T. Y., Homsi, J., Dowell, J. E., Koh, A. Y., Raj, P., Fattah, F. J., Wang, Y., Basava, V. S., et al. (2022) · Cancers · doi:10.3390/cancers14051327 · Cited by 24
The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer
Sillo, T. O., Beggs, A. D., Middleton, G., & Akingboye, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065767 · Cited by 28
The Gut Microbiome and Pancreatic Cancer Development and Treatment
Attebury, H., & Daley, D. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000647 · Cited by 30
Cheng, Y., Ling, F., Li, J., Chen, Y., Xu, M., Li, S., & Zhu, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190850 · Cited by 26
Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review
Muscolino, P., Granata, B., Omero, F., Pasquale, C. D., Campana, S., Calabrò, A., D’Anna, F., Drommi, F., Pezzino, G., Cavaliere, R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1247614 · Cited by 29
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 33
Wang, W., Fan, J., Zhang, C., Huang, Y., Chen, Y., Fu, S., & Wu, J. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127668 · Cited by 25
The impact of the human gut microbiome on the treatment of autoimmune disease
Nayak, R. R., & Orellana, D. A. (2024) · Immunological Reviews · doi:10.1111/imr.13358 · Cited by 23
Tak, U., Schinkel, K., Walth, P., Tay, J. W., Hartwick, E. W., & Whiteley, A. T. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.03.004 · Cited by 32
Gut Microbiota–Related Biomarkers in Immuno-Oncology
Silva, C. A. C., Fidelle, M., Almonte, A. A., Derosa, L., & Zitvogel, L. (2025) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061124-102218 · Cited by 22
Cancer microbiota: a focus on tumor-resident bacteria
Vella, G., & Rescigno, M. (2025) · EMBO Reports · doi:10.1038/s44319-025-00482-w · Cited by 26
Chen, L., Li, B., Zu, M., Reis, R. L., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 24
Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis
Liang, Y., Chen, W., Zhang, Y., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02328-2 · Cited by 36
Harnessing the microbiome for cancer therapy
Hajjar, R., Mars, R. A. T., & Kashyap, P. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01268-6 · Cited by 34
Microbiome modulation of tumorigenesis and immune responses
Chen, Y., Fang, Y., Lyu, Z., Tian, Y., Niu, S., Li, Y.-R., & Yang, L. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01208-9 · Cited by 30
Epidermis as a Platform for Bacterial Transmission
Baquero, F., Saralegui, C., Marcos-Mencía, D., Ballestero, L., Vañó-Galván, S., Moreno‐Arrones, Ó. M., & del Campo, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774018 · Cited by 25
Potential Role of Vaginal Microbiota in Ovarian Cancer Carcinogenesis, Progression and Treatment
Zhao, X., Liu, Z., & Chen, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030948 · Cited by 28
Zeng, Y., Shi, Q., Liu, X., Tang, H. T., Lu, B., Zhou, Q., Xu, Y., Chen, M., Zhao, J., Li, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1144534 · Cited by 26
Crosstalk between gut microbiota and RNA N6-methyladenosine modification in cancer
Su, H., Cheung, H., Lau, H. C.-H., Chen, H., Zhang, X., Wang, Y., Wang, Y., Chan, M. T. V., Wu, W. K. K., & Chen, H. (2023) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuad036 · Cited by 25
From the Colon to the Liver: How Gut Microbiota May Influence Colorectal Cancer Metastatic Potential
Mignini, I., Piccirilli, G., Galasso, L., Termite, F., Esposto, G., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020420 · Cited by 26
Gut microbiota and immunosenescence in cancer
Xu, Y., He, C., Xi, Y., Zhang, Y., & Bai, Y. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.07.004 · Cited by 24
Najmi, M., Tran, T., Witt, R. G., & Nelson, K. C. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00810-1 · Cited by 21
The Role of Gut Microbiota in Modulating Cancer Therapy Efficacy
Madkour, M. A., Altaf, R. A., Sayed, Z. S., Yasen, N. S., Elbary, H. A., Elsayed, R. A., Mohamed, E. N., Toema, M., Wadan, A.-H. S., Nafady, M. H., et al. (2024) · Advanced Gut & Microbiome Research · doi:10.1155/2024/9919868 · Cited by 25
Gut modulation to regulate NF-κB in colorectal and gastric cancer therapy and inflammation
Kearns, R. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04118-9 · Cited by 26
Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma
Huo, R., Xu, Q.-G., You, Y., Chen, Y., Su, G.-J., Yang, K.-R., Xiao, Y.-P., Zhong, X., Li, Y.-J., Sun, P., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00960-3 · Cited by 26
Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice
Zerdan, M. B., Niforatos, S., Nasr, S., Nasr, D., Ombada, M., John, S., Dutta, D., & Lim, S. H. (2022) · Cancers · doi:10.3390/cancers14030691 · Cited by 28
Gut Microbiota and Immunotherapy
Xu, X., & Ying, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.945887 · Cited by 25
The intestinal microbiota in colorectal cancer metastasis – Passive observer or key player?
Patel, M., McAllister, M. J., Nagaraju, R. T., Al-Badran, S. S. F., Edwards, J., McBain, A. J., Barriuso, J., & Aziz, O. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103856 · Cited by 21
The microbiome and gynecologic cancer: cellular mechanisms and clinical applications
Chalif, J., Wang, H., Spakowicz, D. J., Quick, A. M., Arthur, E. K., O’Malley, D. M., & Chambers, L. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004894 · Cited by 28
Liu, L., Liang, L., Luo, Y., Han, J., Lu, D., Cai, R., Sethi, G., & Mai, S. (2024) · Research · doi:10.34133/research.0529 · Cited by 22
Čierniková, S., Ševčíková, A., Novisedláková, M., & Mego, M. (2024) · Cancers · doi:10.3390/cancers16244271 · Cited by 24
The microbiome as a therapeutic co-driver in melanoma immuno-oncology
Bautista, J., Chávez, J. A. V., Larco, D. S. B., Martín-Aguilera, R., & López‐Cortés, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1673880 · Cited by 28
Cancer ecosystems: A dynamic interplay across scales
Quail, D. F., & Joyce, J. A. (2026) · Cell · doi:10.1016/j.cell.2026.03.003 · Cited by 30
Venkatakrishnan, K., Gupta, N., Smith, P. F., Lin, T., Lineberry, N. B., Ishida, T., Wang, L., & Rogge, M. C. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2591 · Cited by 23
The cure from within? a review of the microbiome and diet in melanoma
Kumar, P. R., Brazel, D., DeRogatis, J. M., Goldstein, J. B., Whiteson, K., Chow, W. A., Tinoco, R., & Moyers, J. T. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10029-3 · Cited by 25
Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
Vasavada, S. R., Panneerselvam, K., Amin, R., Varatharajalu, K., Okhuysen, P. C., Oliva, I. C. G., Wang, J., Grivas, P., Thomas, A. S., & Wang, Y. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0722 · Cited by 22
Diet-gut microbial interactions influence cancer immunotherapy
Wang, X., & Geng, S.-T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1138362 · Cited by 23
Deng, X., Zhang, C., Yang, Y., Wang, J., Ye, X., Gu, J., Zhang, X., & Jin, H. (2023) · Journal of Cancer · doi:10.7150/jca.88854 · Cited by 21
Precision strategies for cancer treatment by modifying the tumor-related bacteria
Lu, H., Wang, Q., Liu, W., Wen, Z., & Li, Y. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11491-9 · Cited by 22
The role of gut microbiome in immune modulation in metastatic renal cell carcinoma
Deluce, J. E., Vareki, S. M., & Fernandes, R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221122714 · Cited by 22
Microbiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19
The role of the gut microbiome in modulating immunotherapy efficacy in colorectal cancer
Zuo, S., Huang, Y., & Zou, J. (2024) · IUBMB Life · doi:10.1002/iub.2908 · Cited by 23
Effect of Gut Dysbiosis on Onset of GI Cancers
Kumari, S., Srilatha, M., & Nagaraju, G. P. (2024) · Cancers · doi:10.3390/cancers17010090 · Cited by 23
Gut microbiota in cancer initiation, development and therapy
Zhang, R., Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2831-x · Cited by 19
Hakozaki, T., Tanaka, K., Shiraishi, Y., Sekino, Y., Mitome, N., Okuma, Y., Aiba, T., Utsumi, T., Tanizaki, J., Azuma, K., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.02.026 · Cited by 26
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546717 · Cited by 27
Gronich, N., Geva‐Zatorsky, N., Herren, R., Kelly, L., Cohen, Z., Zhou, H., Chen, Y. H., Shah, K., Robinson‐Catala, T. A., Frisby, G., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70066 · Cited by 26
Metadata
- Authors
- Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., Brosh-Nissimov, T., Eshet, Y., Ben-Simon, S., Ziv, O., Khan, M. A. W., Amit, M., Ajami, N. J., Barshack, I., Schachter, J., Wargo, J. A., Koren, O., Markel, G., & Boursi, B.
- Affiliations
- Tel Aviv University (IL)
- The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Bar-Ilan University (IL)
- Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
- University of Pennsylvania (US)
- Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Baruch, Erez N.
- Markel, Gal
- Boursi, Ben
- ORCID
- Baruch, Erez N.
- Youngster, Ilan
- Ortenberg, Rona
- Lahat, Adi
- Katz, Lior
- Adler, Katerina
- Raskin, Stephen
- Bloch, Naamah
- Rotin, Daniil
- Anafi, Liat
- Avivi, Camila
- Melnichenko, Jenny
- Steinberg-Silman, Yael
- Mamtani, Ronac
- Harati, Hagit
- Asher, Nethanel
- Shapira-Frommer, Ronnie
- Eshet, Yael
- Khan, Md Abdul Wadud
- Amit, Moran
- Ajami, Nadim J.
- Barshack, Iris
- Schachter, Jacob
- Wargo, Jennifer A.
- Koren, Omry
- Markel, Gal
- Boursi, Ben
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 602-609
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3111836013
- Semantic Scholar
- 20052eb45af3e9cf18b231c32b34bc26b96d2259
- Cited by
- 1,757
- References
- 65
- Citations by year
- 2026: 360 · 2025: 328 · 2024: 272 · 2023: 326 · 2022: 299 · 2021: 171
- FWCI
- 71.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- fecal microbiota transplantation, metastatic melanoma, anti-PD-1 therapy, gut microbiota, tumor microenvironment, immune cell infiltration, feasibility and safety
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Nivolumab, Adult, Female, Humans, Immunotherapy, Intestinal Mucosa, Male, Melanoma, Middle Aged, Skin Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Microenvironment, Transcriptome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.